Suppliers / COSMA

COSMA

Italy 2 duplicate records merged Updated 9 July 2026

COSMA is an API manufacturer based in Italy. It holds 34 active US drug master files and 4 valid CEPs across a filed portfolio of 18 molecules. Its most recent recorded inspection, by US FDA, closed on 17 June 2022 as VAI.

34
active US DMFs
4
valid CEPs
2
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 17 June 2022 VAI US FDA
  • 15 January 2016 VAI US FDA
  • 22 March 2013 VAI US FDA
  • 10 July 2009 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Italy, Italy 3002806754
Ciserano, Italy Not on file

What they file, and where

Molecule Regulators Docs
Torasemide EDQM, US FDA 5
Hydroxyzine US FDA 4
Propranolol SFDA (Saudi Arabia), US FDA 4
Amisulpride EDQM, US FDA 3
Gliclazide SFDA (Saudi Arabia), US FDA 3
Ketoprofen EDQM, US FDA 3
Cetirizine US FDA 2
Diclofenac US FDA 2
Labetalol US FDA 2
Levomilnacipran US FDA 2
Show all 18 molecules on file
Metoclopramide US FDA 2
Milnacipran US FDA 2
Oxaprozin US FDA 2
Pyrantel US FDA 2
Ranolazine US FDA 2
Cetirizine Dihydrochloride SFDA (Saudi Arabia) 1
Hydroxyzine Dihydrochloride SFDA (Saudi Arabia) 1
Rifaximin EDQM 1

Also appears on these molecule pages

Comparing suppliers?

Choose your molecules and target markets. COSMA comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 1 active litigation matter is on record.
  • The most recent inspection outcome was VAI, on 17 June 2022.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability